All

DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions
9 November 2020

DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions

A consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million...

Read more
BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD
3 November 2020

BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the...

Read more
Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round
27 October 2020

Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round

Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round. The company develops monoclonal antibodies for oral...

Read the press release
LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding
29 September 2020

LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding

LARQ was started with a simple vision where innovative technology can be combined with inspirational design to help people access pristine drinking water easily and...

Read the press release